Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Unknown 1Completed 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Thoracic 1

Conditions

Small Cell Lung Carcinoma 6Ovarian Neoplasms 6Neuroblastoma 3Carcinoma, Ovarian Epithelial 3Uterine Cervical Neoplasms 2Sarcoma, Ewing 2Sarcoma, Clear Cell 2Sarcoma 2Myoepithelioma 2Liposarcoma, Myxoid 2Histiocytoma, Angiomatoid Fibrous 2Fallopian Tube Neoplasms 2Desmoplastic Small Round Cell Tumor 2Chondrosarcoma, Extraskeletal Myxoid 2Neoplasms 1Myelodysplastic Syndromes 1Malignant mesenchymal tumor 1Lung Neoplasms 1Leukemia 1Fibroma 1Extensive Stage Small Cell Lung Cancer 1Endometrial Neoplasms 1Brain Neoplasms 1Anemia, Refractory, with Excess of Blasts 1

Interventions

camrelizumab 2anlotinib 2Etoposide 2Carboplatin 2tislelizumab 1spartalizumab 1apatinib 1Topotecan 1Temozolomide 1Drug Therapy 1130-nm albumin-bound paclitaxel 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Unknown × Extensive Stage Small Cell Lung Cancer × Topotecan × Clear all
NCT04213937 2019-12-30

Nab-paclitaxel Versus Topotecan As Second-Line Treatment for Patients With Extensive Stage Small Cell Lung Cancer

Cancer Institute and Hospital, Chinese Academy of Medical Sciences

Phase 2 Unknown
386 enrolled
Thoracic

Extensive Stage Small Cell Lung Cancer

Data powered by HemOnc (CC BY 4.0) Colophon âš¡